BTG touts digital patient engagement platform with TheraSphere treatment

BTG (LON:BTG) touted data last week from a pilot study of its digital patient engagement platform IO Loop in patients with primary hepatocellular carcinoma undergoing treatment with the company’s TheraSphere transarterial radioembolization therapy.
The study found that patients experienced sustained quality of life up to 3 months after treatment. The company called the study of its novel data collection tool the “the first-of-its-kind” in interventional oncology.
Get the full story at our sister site, Drug Delivery Business News.
The post BTG touts digital patient engagement platform with TheraSphere treatment appeared first on MassDevice.

Source: Mass Device - June 12, 2017 Category: Medical Devices Authors: Sarah Faulkner Tags: Clinical Trials Drug-Device Combinations Oncology Patient Monitoring Vascular BTG Source Type: news